For men with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggests a preliminary clinical trial in the Journal of Urology.
New hormonal agent may slow progression of early-stage prostate cancer during active surveillance

Comments